QualityStocksNewsBreaks – NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) Wins BOLD Awards VII Healthcare Honor, Engages IBN For Investor Outreach
This article has been disseminated on behalf of NurExone Biologic and may include paid advertising. NurExone Biologic (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) announced it received first place in the Healthcare category at the BOLD Awards VII Gala held March 27, 2026, in Barcelona, recognizing its leadership in exosome-based therapies for central nervous system injuries, and also provided a corporate update highlighting its selection by a panel of global industry leaders. The company further reported plans to engage Investor Brand Network (IBN), subject to TSX Venture Exchange approval, to support investor awareness efforts beginning April 1, 2026, including distribution of news and updates across more than 5,000 outlets, with a monthly fee of $6,500 under…